Recently, Thermo Fisher Technologies (hereinafter referred to as: Thermo Fisher), a global leader in enabling scientific and technological progress, opened a factory in Hangzhou, China. As an important step in Thermo Field’s global business layout, the official opening of the plant will help pharmaceutical and biotechnology companies more quickly deliver therapeutic drugs to patients and meet the demand for development and manufacturing capabilities of biologics and sterile preparations in China and overseas.
Thermo Fisher Technology China Hangzhou factory
“The Hangzhou facility is a strategic addition to our global pharmaceutical service network and a new example of our commitment to meeting the needs of our customers around the world.” Mike Shafer, Thermo Feld’s senior vice president and president of pharmaceutical services, said, “We will continue to invest in our ability to meet our customers’ manufacturing needs and help them serve more patients around the world.”
The 80,000-square-meter cGMP facility has clinical and commercial production capabilities for bulk solutions and formulations, including process development, cell line development, bio-bulk solution production and aseptic filling. In the future, the plant will also provide commercial packaging services for customers. The Hangzhou facility is equipped with a range of advanced technologies including Thermo Fly’s 2,000-litre HyPerforma single-use bioreactor and associated single-use equipment, with the

DS200IIBDG1AGA

possibility of future bioreactor capacity up to 5,000 litres through Thermo Fly’s DynaDrive technology.
Thermo Fisher Technology China Hangzhou factory
The facility implements rigorous quality control processes that meet or exceed regulatory requirements set by the National Drug Administration of China (NMPA), the U.S. Food and Drug Administration (FDA), and European and other regional authorities.
“Thermo Fisher has been in China for 40 years and continues to serve the Chinese market through its bioindustrial, clinical research and pharmaceutical services businesses.” Hann Pang, president of Thermo Fly China, said, “Adhering to the localization strategy of ‘rooted in China, serving China’, Thermo Fly will continue to improve its service capabilities in the biomedical industry chain, provide more comprehensive support for pharmaceutical and biotechnology companies in China and around the world, and enable more local innovations to go global.”
The completion of the Hangzhou facility in China is an important demonstration of Thermo Field’s comprehensive end-to-end service capabilities in contract development and manufacturing (CDMO) across the globe. With the newly opened Hangzhou facility, combined with its existing capabilities in clinical packaging and logistics, Thermo Field can now seamlessly link the entire biopharmaceutical process from molecular development to accelerating the delivery of critical medicines to patients, providing customers with end-to-end solutions.